Increased plasma HDL-cholesterol and apo A-I in breast cancer patients undergoing adjuvant tamoxifen therapy
- 1 August 2000
- journal article
- research article
- Published by Elsevier in Clinical Biochemistry
- Vol. 33 (6) , 513-516
- https://doi.org/10.1016/s0009-9120(00)00160-0
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- The Impact of Estrogen Replacement Therapy and Raloxifene on Osteoporosis, Cardiovascular Disease, and Gynecologic CancersAnnals of Pharmacotherapy, 1999
- Effect of tamoxifen on lipids and lipid metabolising marker enzymes in experimental atherosclerosis in Wistar ratsMolecular and Cellular Biochemistry, 1997
- Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women After 5 Years of TreatmentJNCI Journal of the National Cancer Institute, 1994
- Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancerCancer, 1994
- Potential Role of Tamoxifen in Prevention of Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients With Node-Negative Breast CancerJNCI Journal of the National Cancer Institute, 1990
- Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988
- Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up StudyJAMA, 1983